Effect of oral curcuden on multiple sclerosis patients

Evaluation of safety and efficacy of oral curcuden on remitting and relapsing multiple sclerosis patients (RRMS): clinical trial study of Phase A2

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170128032241N2

Enrollment

Registered

2018-02-16

Start date

2017-10-23

Completion date

Unknown

Last updated

2019-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple sclerosis. Demyelinating diseases of the central nervous system(Multiple sclerosis)

Interventions

Intervention 1: Intervention group 1: 34 RRMS patients who received at least 6 months of first line treatment of MS (beta-interferon) but have clinically experienced at least one relapse during medica

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: RRMS patients who will receive first-line treatment drugs for one year Have at least one relapse or active lesion At least one month has passed since the last attack of the disease At least one month ha passed from the patient's corticosteroids Average age of 18 to 60 years 0 <EDSS <5.5 No curcumin contraindications

Exclusion criteria

Exclusion criteria: Progressive MS patients Patients who have contraindicated curcumin or similar substances The presence of any internal or systemic illness (such as anemia or liver problems)

Design outcomes

Primary

Measure	Time frame
Active lesions in the brain and spinal cord (plaque). Timepoint: Before the intervention (month 0) and the sixth month after the intervention. Method of measurement: MRI.;Blood inflammatory factors. Timepoint: Before the intervention (month 0) and the sixth month after the intervention. Method of measurement: Blood Test.	—

Secondary

Measure	Time frame
Clinical relapse within 6 months. Timepoint: Every 6 months. Method of measurement: MRI.;Effect of medication on other MRI parameters such as T2 lesions, new T2 lesions and brain atrophy. Timepoint: Every 6 months. Method of measurement: MRI.;Effect of medication on changes in inflammatory and anti-inflammatory mediators. Timepoint: Before intervention and 6 months after intervention. Method of measurement: Blood test.;Effect of medication on improving patient lifestyle. Timepoint: Before intervention and 6 months after intervention. Method of measurement: EDSS Criteria, Fatigue, Focus, Balance .	—

Measure

Time frame

Clinical relapse within 6 months. Timepoint: Every 6 months. Method of measurement: MRI.;Effect of medication on other MRI parameters such as T2 lesions, new T2 lesions and brain atrophy. Timepoint: Every 6 months. Method of measurement: MRI.;Effect of medication on changes in inflammatory and anti-inflammatory mediators. Timepoint: Before intervention and 6 months after intervention. Method of measurement: Blood test.;Effect of medication on improving patient lifestyle. Timepoint: Before intervention and 6 months after intervention. Method of measurement: EDSS Criteria, Fatigue, Focus, Balance .

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Mohajeri

Alborz Nanomed Tech Co.

mohajeri_maryam@yahoo.com+98 21 6691 9151

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026